Epizyme Revenue and Competitors

Boston, MA USA

Location

$834.1M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Epizyme's estimated annual revenue is currently $34.2M per year.(i)
  • Epizyme's estimated revenue per employee is $126,741
  • Epizyme's total funding is $834.1M.
  • Epizyme's current valuation is $225.5M. (January 2022)

Employee Data

  • Epizyme has 270 Employees.(i)
  • Epizyme grew their employee count by -28% last year.

Epizyme's People

NameTitleEmail/Phone
1
Senior Director, Field Medical Training & DevelopmentReveal Email/Phone
2
East Region Director, Field Medical AffairsReveal Email/Phone
3
Associate Director, Clinical Data ManagementReveal Email/Phone
4
Director, BiologyReveal Email/Phone
5
Associate Director Epigenetic TherapyReveal Email/Phone
6
Senior Director, Regulatory Affairs CMCReveal Email/Phone
7
Director, Thought Leader Engagement, Hematology / Oncology / Rare DiseaseReveal Email/Phone
8
Senior Manager Clinical Data ManagementReveal Email/Phone
9
Senior Manager, Forecasting, Analytics and New Product PlanningReveal Email/Phone
10
Senior HRIS and Compensation ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Epizyme?

Epizyme, Inc. is a late-stage biopharmaceutical company rewriting therapy for cancer and other serious diseases through novel epigenetic medicines. Our pipeline is led by tazemetostat, an investigational agent that is an orally administered, first-in-class small molecule EZH2 inhibitor for the treatment of multiple types of hematological malignancies and genetically defined solid tumors. The company also is developing a novel G9a program with its next development candidate, EZM8266, which is targeting sickle cell disease. By focusing on the genetic drivers of disease, Epizyme's science seeks to match targeted medicines with the patients who need them.

keywords:N/A

$834.1M

Total Funding

270

Number of Employees

$34.2M

Revenue (est)

-28%

Employee Growth %

$225.5M

Valuation

N/A

Accelerator

Epizyme News

2022-04-19 - Mass. biotechs have cut jobs in 2022 - Boston Business Journal

Epizyme: Epizyme Inc. (Nasdaq: EPZM) revealed in its fourth-quarter 2021 earnings report that it had let go of about 12% of its employees,...

2022-04-06 - Epizyme Announces Inducement Grants Under Nasdaq ...

Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). April 06, 2022 07:00 AM Eastern Daylight Time. CAMBRIDGE, Mass.--(BUSINESS...

2022-04-06 - Epizyme chief medical officer Shefali Agarwal resigns

Epizyme (NASDAQ:EPZM) Chief Medical and Development Officer ... Year to date through Wednesday's close, Epizyme (EPZM) shares are down ~68%.

2019-12-19 - FDA panel recommends approval of Epizyme drug for rare cancer

Shares of Epizyme rose 35.6% on the Nasdaq Wednesday following the news, before leveling off and by Thursday afternoon trading at around 8% above their Wednesday closing price. “We are incredibly pleased by ODAC’s unanimous support for the benefit-risk of tazemetostat in ES, and we appreciate t ...

2019-11-05 - Epizyme Raises Up to $270M in Funding

Epizyme, Inc. (Nasdaq: EPZM), a Cambridge, Mass.-based late-stage biopharmaceutical company developing novel epigenetic therapies, closed funding agreements that, in aggregate, could bring in up to $270m in capital. The backers were Royalty Pharma and its affiliate Pharmakon Advisors. As part o ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$30.3M2706%N/A
#2
$24.5M271-5%$656.6M
#3
$79.8M275-1%$3M
#4
$81.7M275-18%N/A
#5
$62.8M27847%$240.8M